Pancreatic Cancer Research

ResearcherRadboud University Medical CenterActive in the last 2 years

Marion B.M. van der Kolk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0294-0496; OpenAlex author ID A5001300340. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 5 papers · 2025: 3 papers · 2026: 7 papers

Papers 20

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  3. How do patient-reported and observed measures of shared decision-making compare in pancreatic cancer care? Insights from a cross-sectional study. Co-author DOI 10.1016/j.pec.2026.110367↗
  4. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  5. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  6. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  7. Patient Experiences of Oncological Care in Comprehensive Cancer Networks: A Qualitative Study in Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-9113970/v1↗
  8. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  9. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  10. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  11. Barriers and facilitators of healthcare professionals in integrating shared decision-making in pancreatic cancer treatment: A network approach. Last author DOI 10.1002/cam4.70218↗
  12. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  13. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  14. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  15. Determinants of treatment decisions of patients with pancreatic cancer in shared decision-making: A qualitative study Last author DOI 10.22541/au.170670344.49523538/v1↗
  16. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  17. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, obs… Co-author DOI 10.1093/bjsopen/zrac174↗
  18. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  19. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreati… Co-author DOI 10.1186/s12885-021-08031-z↗
  20. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multi… Co-author DOI 10.1186/s13063-016-1262-z↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ignace H. J. T. de Hingh · 9 shared papers, 2016–2026 · strength 1.32
  2. Bert A. Bonsing · 9 shared papers, 2016–2026 · strength 1.32
  3. Marc G. Besselink · 9 shared papers, 2016–2026 · strength 1.32
  4. Philip Jan van der Wees · 4 shared papers, 2024–2026 · strength 1.16
  5. Hjalmar C. van Santvoort · 7 shared papers, 2021–2026 · strength 1.14
  6. Casper H.J. van Eijck · 8 shared papers, 2016–2026 · strength 1.08
  7. Bas Groot Koerkamp · 7 shared papers, 2021–2026 · strength 1.04
  8. Johanna W. Wilmink · 6 shared papers, 2021–2026 · strength 1.01
  9. Marjolein Y.V. Homs · 6 shared papers, 2021–2026 · strength 1.01
  10. Gijs A. Patijn · 7 shared papers, 2016–2026 · strength 0.96
  11. Geertjan van Tienhoven · 7 shared papers, 2016–2026 · strength 0.95
  12. Rosella Hermens · 3 shared papers, 2024–2026 · strength 0.91
  13. Joannes Franciscus Adrianus Gerardus van Broekhoven · 3 shared papers, 2024–2026 · strength 0.91
  14. Jacob L. van Dam · 5 shared papers, 2021–2026 · strength 0.77
  15. Esther N. Dekker · 4 shared papers, 2023–2026 · strength 0.67
  16. Judith de Vos‐Geelen · 5 shared papers, 2016–2026 · strength 0.66
  17. Quisette P. Janssen · 4 shared papers, 2021–2026 · strength 0.64
  18. Stefan A.W. Bouwense · 3 shared papers, 2025–2026 · strength 0.63
  19. Sebastiaan Festen · 4 shared papers, 2016–2026 · strength 0.53
  20. Vincent Erwin de Meijer · 3 shared papers, 2023–2026 · strength 0.52
  21. J. Sven D. Mieog · 3 shared papers, 2023–2025 · strength 0.46
  22. Babs M. Zonderhuis · 3 shared papers, 2021–2025 · strength 0.42
  23. Thomas F. Stoop · 2 shared papers, 2025–2026 · strength 0.39
  24. Eva Versteijne · 3 shared papers, 2016–2025 · strength 0.34
  25. Vincent B. Nieuwenhuijs · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.